I agree that this site is using cookies. You can find further informations here.
X
Colombel, F.
721  results:
Search for persons X
?
1

P983 Treatment of patients with moderate-to-severe Crohn's ..:

Sands, B E ; Dubinsky, M C ; D'Haens, G...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1782-i1783 , 2024
Link: https://doi.org/10.1093/..
 
?
2

DOP18 Efficacy of risankizumab versus ustekinumab by baseli..:

Peyrin-Biroulet, L ; Colombel, J F ; D'Haens, G...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i104-i105 , 2024
Link: https://doi.org/10.1093/..
 
?
3

DOP33 Distinct perturbances in metabolic pathways associate..:

Bourgonje, A R ; Ibing, S ; Argmann, C...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i131-i133 , 2024
Link: https://doi.org/10.1093/..
 
?
4

P253 Knowledge and acceptability of the Lémann Index to mea..:

Wong, C ; Torres, J ; Burisch, J...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i606-i607 , 2024
Link: https://doi.org/10.1093/..
 
?
5

P593 Efficacy of Risankizumab in Patients With Moderately t..:

Panaccione, R ; Louis, E ; Colombel, J F...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1153-i1155 , 2024
Link: https://doi.org/10.1093/..
 
?
6

P734 Super-responders in patients with moderate-to-severe C..:

Schreiber, S W ; Sands, B E ; Hanauer, S B...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1375-i1376 , 2024
Link: https://doi.org/10.1093/..
 
?
7

P902 Subcutaneous infliximab (CT-P13 SC) as maintenance the..:

Colombel, J F ; Hanauer, S B ; Sandborn, W J...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1653-i1654 , 2024
Link: https://doi.org/10.1093/..
 
?
8

P623 Network meta-analysis to evaluate the comparative effi..:

Schreiber, S W ; Danese, S ; Colombel, J F...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1198-i1199 , 2024
Link: https://doi.org/10.1093/..
 
?
9

DOP68 Natural history of isolated Crohn's Disease perianal ..:

Sangmo, L ; Quraishi, B ; Rajauria, P...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i196-i198 , 2024
Link: https://doi.org/10.1093/..
 
?
10

P104 Per- and poly-fluoroalkyl substances (PFAS) exposure i..:

Agrawal, M ; Midya, V ; Picker, M...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i386-i387 , 2024
Link: https://doi.org/10.1093/..
 
?
11

P439 Mild Crohn's disease is characterized by a unique seru..:

Bourgonje, A R ; Ibing, S ; Argmann, C...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i897-i898 , 2024
Link: https://doi.org/10.1093/..
 
?
12

P1008 Efficacy and safety of retreatment with upadacitinib ..:

Panaccione, R ; Colombel, J F ; Dubinsky, M...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1821-i1822 , 2024
Link: https://doi.org/10.1093/..
 
?
13

DOP11 Disease clearance after 16 weeks of treatment with ve..:

Jairath, V ; Zou, G ; Adsul, S...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i92-i93 , 2024
Link: https://doi.org/10.1093/..
 
?
14

P409 Optimal endoscopic healing thresholds defined by MM-SE..:

Narula, N ; Wong, E C ; Dulai, P S...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i847-i848 , 2024
Link: https://doi.org/10.1093/..
 
?
15

OP13 Anti-integrin αvβ6 autoantibodies are increased in PSC..:

Bloemen, H ; Livanos, A ; Martins, A...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i24-i26 , 2024
Link: https://doi.org/10.1093/..
 
1-15